BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology, reported Q2 2025 revenue of $13.2 million versus $17.0 million a year ago, reflecting strong e-commerce growth offset by declines in healthcare operations from lower prescription volumes and reduced 340B contract revenue. Gross margin fell to 21.8% from 34.5% on mix shifts and industry drug price pressures. Operating expenses dropped to $4.7 million from $16.8 million on the absence of prior-year non-recurring charges and cost-cutting measures, producing a net loss of $1.8 million, or ($0.07) per share, compared to a $5.3 million loss last year. The company ended the quarter with $16.6 million in cash and expects over $1 million in annual expense savings. Recent initiatives include technology upgrades, talent recruitment, and sales expansion in 340B and long-term care, along with growing connectivity service contracts and OPKO product sales in China. Management expects to announce further operational and strategic developments within 60 days

To view the full press release, visit: https://ibn.fm/PrJ90

About NextPlat Corp

NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc.

NOTE TO INVESTORS: The latest news and updates relating to NXPL are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN